Table 6.
Allele frequencies in patients included in the population pharmacokinetic model
| Gene | Frequency of allele in patients who received indicated drug(s) (n)a |
||||
|---|---|---|---|---|---|
| AM/DHAb (135) | LF/DLFb (143) | AS/DHAb and MQ (63) | DHA (56) | PPQ (60) | |
| CYP2A6*2 | 0 (134) | 0 (142) | 0 (59) | 0 (55) | 0 (59) |
| CYP2B6*5 | 1.9 (134) | 1.8 (142) | 5.2 (58) | 1.8 (56) | 1.7 (60) |
| CYP2B6*6 | 34 (110) | 34 (116) | 42 (43) | 33 (44) | 33 (46) |
| CYP2C8*3 | 0 (62) | 0 (66) | 0 (36) | 0 (33) | 0 (37) |
| CYP2C9*3 | 0 (118) | 0 (125) | 8.5 (59) | 4.5 (56) | 4.2 (60) |
| CYP2C9*5 | 0.9 (118) | 0.8 (125) | 0 (59) | 0 (56) | 0 (60) |
| CYP2C19*3 | 0.8 (128) | 0.7 (136) | 3.3 (60) | 2.7 (56) | 2.5 (60) |
| CYP2D6*4 | 4.1 (122) | 4.3 (128) | 0 (50) | 0 (20) | 0 (22) |
| CYP2D6*10 (100C→T) | 6.4 (125) | 6.9 (130) | 65 (52) | 53 (32) | 51 (35) |
| CYP2D6*10 (4180G→C) | 75 (128) | 75 (136) | 72 (58) | 69 (56) | 70 (60) |
| CYP2D6*17 (1023C→T) | 22 (105) | 21 (112) | 0 (50) | 0 (13) | 0 (14) |
| CYP2D6*17 (2859C→T) | 65 (36) | 62 (38) | 11 (19) | 7.1 (28) | 6. 5 (31) |
| CYP3A4*1B | 73 (121) | 73 (129) | 4.7 (53) | 1.3 (39) | 2.4 (41) |
| CYP3A5*3 | 19 (130) | 19 (138) | 70 (59) | 59 (56) | 61 (60) |
| NAT2*5 | 36 (129) | 37 (137) | 5.9 (59) | 8.0 (56) | 7.5 (60) |
| NAT2*6 | 27 (134) | 27 (142) | 35 (58) | 46 (56) | 44 (60) |
| NAT2*7 | 2.2 (134) | 2.5 (142) | 23 (59) | 19 (55) | 20 (59) |
| NAT2*14 | 14 (127) | 14 (135) | 5.1 (59) | 0 (56) | 0 (60) |
a
Frequencies are percentages of patients in whom the SNP was found, from among the total patient population that received the drug(s). Values in parentheses are numbers of patients for whom SNP data were available for each group (compared to the total n, show at the top of each column).
b
Parent drug/metabolite.